Year: 2009
Type: article
Study design: Observational Study
Abstract: BACKGROUND: HIV-associated neurologic disorders (HAND) continue to develop in many patients with HIV. CSF amyloid measurements in HAND have been reported to be similar to those in dementia of the Alzheimer type (DAT). Confirmatory evaluation of this finding in carefully evaluated subjects is needed. METHODS: CSF specimens were obtained from subjects clinically categorized with normal cognition from the general population, HIV+ subjects with normal cognition, HIV+ subjects with impaired cognition, or presumed HIV- subjects with mild DAT. CSF measurements of beta-amyloid((1-42)) (Abeta42), beta-amyloid((1-40)) (Abeta40), total tau (t-tau), and phosphorylated tau (p-tau181) were performed. RESULTS: CSF Abeta42 measured in 49 HAND subjects had a median level of 501 pg/mL, which was lower than that of 50 controls of similar age who had median of 686 pg/mL (p < 0.0001) or 21 HIV+ subjects without cognitive impairment who had median of 716 pg/mL (p < 0.003). HAND subjects had similar CSF Abeta42 to 68 subjects with mild DAT. There was no difference of CSF Abeta40 between the groups. Tau and p-tau181 was elevated in DAT, but slightly lower than control in both HIV+ groups. CONCLUSIONS: beta-Amyloid((1-42)) (Abeta42) measurements in CSF of cognitively impaired patients with HIV are similar to those in patients with mild dementia of the Alzheimer type (DAT). Normal or slightly depressed CSF tau and p-tau181 measurements distinguish these patients with HIV-associated neurologic disorders (HAND) from patients with DAT. Further evaluation of amyloid metabolism in patients with HIV cognitive disorder is needed to understand the implications of depressed CSF Abeta42 in the setting of HAND.
Source: Neurology
Authors: D. B. Clifford, A. M. Fagan, D. M. Holtzman, J. C. Morris, M. Teshome, A. R. Shah, J.S.K. Kauwe
Institutions: Brigham Young University, Washington University in St. Louis
Language: English
Topic: HIV Research and Treatment
Subfield: Virology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: bronze
Funders: Alzheimer's Association, Dana Foundation, Bristol-Myers Squibb, Eli Lilly and Company, Pfizer, AstraZeneca, GlaxoSmithKline, Gilead Sciences, Biogen, Fidelity Foundation, Cure Alzheimer's Fund, Elan, Eisai, Bavarian Nordic, National Institutes of Health, Genentech, Forest Laboratories, Takeda Oncology, Avid Radiopharmaceuticals, National Institute on Aging, National Institute of Mental Health, National Institute on Drug Abuse, National Institute of Neurological Disorders and Stroke
Awards: G104586243, G1574399798, G1602390028, G1622375532, National NeuroAIDS Tissue Consortium Statistics and Data Coordinating Center, G1961535950, G20300921, G2452681398, G2892378086, G298662785, CNS HIV Anti-Retroviral Therapy Effects Research (CHARTER), National Neurological AIDS Bank (NNAB), G4140207963, The Manahattan HIV Brain Bank, Texas Repository for AIDS Neuropathogenesis Research, G4633544157, G5366509656, G5556102405, G5617223781, G561739401, G647771723, Alzheimer's Disease Research Center, G710411779, Healthy Aging and Senile Dementia, Dominantly Inherited Alzheimer Network, G8249868222, G9000039018, G9000060740, G9000077746, G9000133689, G9000138364, G9000239624, G9000241477, G9000292983
OpenAlex ID: W2109624357